Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Benzinga · 2d ago
Leerink Partners analyst Daina Graybosch maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $46 to $49.